In The News — Plex Pharmaceuticals

PRESS RELEASES

2020-07-08 San Diego: Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataracts

2020-02-04 San Diego: Plex Pharmaceuticals Awarded $600,000 Phase I NIH SBIR Grant to Develop Broad-Spectrum Antivirals to Treat Flavivirus Infections

2018-12-03 San Diego: Plex Pharmaceuticals Announces Positive Ex Vivo Efficacy and Top Line In Vivo Ocular Safety Data of CAP1160

2017-08-02 San Diego: Collidion Acquires 80% Stake in Plex Pharmaceuticals

2016-07-13 San Diego: Plex Pharmaceuticals awarded $670,865 grant funding from The Michael J. Fox Foundation for Parkinson's Research.

2015-09-21 San Diego: Plex Pharmaceuticals Announces Continuation of Funding of NIH SBIR Phase I Grant and Key Appointments to Management and Scientific Advisory Board.

2015-05-05 San Diego: Plex Pharmaceuticals awarded Phase I SBIR grant to treat Dengue virus infection.

2013-06-13 San Diego: Plex’s Chairman, Allan E. Rubenstein MD, co-authors a ground-breaking peer reviewed scientific manuscript demonstrating the utility Heat Shock Protein 90 (Hsp90) inhibitors for the treatment of Neurofibromatosis type 2 (NF2).

2012-09-10 San Diego: Allan E. Rubenstein, MD and Khatereh Ahmadi, PhD to assume roles in Plex Pharmaceuticals Inc.

2012-02-12 San Diego: Plex Pharmaceuticals and Professor R. Padmanabhan of Georgetown University announce a collaboration to develop inhibitors of Dengue and West Nile virus proteases.

2011-12-07 San Diego: Plex and LD Biopharma Have Agreed to Provide Integrated Discovery Services for structure-based and fragment-based drug discovery.

2010-09-10 San Diego: Plex receives a $279,068 grant award to develop selective and dual-acting HSP90 and TRAP1 inhibitors

2010-06-07 San Diego: Plex receives a $549,882 grant award to develop novel, selective and potent brain-penetrable small molecule cytosolic Hsp90 inhibitors

2010-05-05 San Diego: Plex receives a $201,930 grant award to develop glucose-dependent partial activators of pancreatic glucokinase

MEDIA

2014-06-20: Interview With Sridhar Prasad, PhD., Founder Of Plex Pharmaceuticals

2011-04-06: California: Safe harbour

2010-09-01: Novel, Selective and Potent Brain-penetrant Small Molecule Inhibitors of Cytosolic Hsp90

2010-06-14: How the Recession Fueled San Diego Biotech Innovation

Partners and Investors

Plex Pharmaceuticals, Inc., is a privately held early stage pharmaceutical company focused on the rapid discovery of drug-like small molecules for underserved needs including CNS/Systemic oncology, degenerative CNS disorders, and infectious diseases.

While the majority of funding has been attained through non-dilutive mechanisms, we are actively seeking corporate partnership and private investment to advance our programs toward an ultimate goal of investigational new drug (IND) filing.

Plex has successfully secured private funding from:

Publications

Calderone R, Sun N, Gay-Andrieu F, Groutas W, Weerawarna P, Prasad S, Alex D, Li D. Antifungal drug discovery: the process and outcomes. Future Microbiol. 2014;9(6):791-805. [Pubmed]

Sridhar G. Prasad, Nicholas, Cosford. Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90 (2013). WO 2013172872 A1[Patent Application]

Lai H, Sridhar Prasad G, Padmanabhan R. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Antiviral Res. 2013 Jan;97(1):74-80. [Pubmed]

G. Sridhar Prasad, Nicholas D.P. Cosford, and Sailen Barik: "Plasmodium Hsp90 as an Antimalarial Target" (2011), in Apicomplexan Parasites, Molecular Approaches toward Targeted Drug Development Drug Discovery in Infectious Diseases (Volume 2), Becker Katja and Selzer Paul M. (Editors). Publisher Wiley-Blackwell.

All trademarks, trade names, or logos mentioned or used are the property of their respective owners.